Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The thing has been halted in Canada for over a month. Maybe two.
You'd be out of your mind to buy it.
What's happened to the PPS here? Yikes!
is cease order/review close to completion? looking to put some money in this ahead of DC vote hype
NO MORE GOOD NEWS!
Or this thing will be down to a dime.
NEWS! Champignon to Begin Offering Esketamine Treatment for Adults With Major Depressive Disorder at the Canadian Rapid Treatment Centre of Excellence https://api.quotemedia.com/supplement/news-story/?webmasterId=102132&storyId=7381263246083467
Thank You! I am only IN IIPR other than SHRMF in that segment. I know controlled use of psychedelics will be a great benefit to mental health someday, I hope soon. Shrmf is only 1000 shares so just a watch and see, for me there. Born in '51 so old and had long ago limited use of Mushrooms, Well I grew them and used them in the early 70's. Do not sterilize your Horsehit in your kitchen oven! I know unless the US stimulus package gets passed legal Cannabis Retail could decline in general. Looks to me like a lot of people's drug of choice for Covid-19 relief was THC. Thanks for the post, I will take a walkabout on the ideas, I like the US company you mentioned with testing. Can't see the name or I destroy my response. My state we can grow our own legally (after several hoops jumped) so for a gardener Retail is Expensive. Wife also grew large QTY in Hawaii in the 70-80's we have the technology. Pray or whatever for stimulus and US pot gets a longer Bump and run. Gonna re-read and note more from your post. Thanks so much.
Good post. As well as Champignon, I too am in Hollister big time. Great things expected there moving forward.
Yes I have been seeing that in watching news. Right now may be a good time. Had sucky day today, need to quit watching each tick of things.!
MindMed is considerably better connected and positioned however, I believe both companies will do well. I just know that if this form of medicine is allowed, MindMed will be the global market leader without question. GL.
Nosnibor, I am curious about which company has the connections and the political wherewithal to make things happen. In the USA it would take a very prominent group to proceed with any efficiency at all, I guess Canada is a bit different......but don't know a darn thing and don't see much news/rumor published. Thanks
I think a position here is worth it. I too recently bought back in and will now just sit back, relax and forget about it for quite some time. To answer your question, you might look at Mind Medicine who are the most credible in this space by popular opinion. Big gains will likely not come quickly but with time and patience, the rewards could be immense. Have a look at some of Shark Tank's Kevin O'Leary's videos on YouTube plus MindMed's latest corporate update video also on YouTube. GL.
OK, I bought a bit of this stock and sold it when it was starting to drop. I bought it again at .61 and have watched it move down. I bought them because I am old and think I would like to have Psilocybin legal for people who can benefit from its use. Champignon Brands seems to be a company that id doing something, anything......I am patient, does any other company look better to you than this one?
Any thoughts or Hallucinations?
Trying to get some feedback, comments!
X
Nope - still suspended.
https://thecse.com/en/listings/diversified-industries/champignon-brands-inc
But it seems they filed the missing paperwork and are now waiting for approval so trading can resume.
https://webfiles.thecse.com/sedar_filings/00048796/2007241402314973.pdf
Has Canadian trading resumed?
Looking for a bagger.
OK. I am back, but have not purchased yet. Sorry to hear Orange County treatment center is off. Glad to hear they are not proceeding with rebranding.
Safe to back into the water.
Oh, that still on up north?
Maybe soon this will make 2 Larrys and head towards a Loonie.
It's a shame our SEC doesn't care about silly little things like missing documents.
It's been halted because they didn't file their shit.
And they don't seem to want it, eh?
It's a Canadian company.
Fortunately they have 364 days left to get there. Get in while you can. Only going in one direction from here.
Yes, everyone knows SHRMF is the best shroom stock...
You post all these negative comments about companies you know little or nothing about? MindMed has NOTHING to do with mushrooms/psybicilin.
I'm obviously invested in both. Legal shrooms and ketamine (SHRMF) will take off sooner than MMEDF will IMHO thus I'll see a sooner return on my investment.
WOW, they're way bigger than I thought they were and I knew they were big.
https://www.sedar.com/DisplayCompanyDocuments.do?lang=EN&issuerNo=00048796
Looks like they know what they're doing to me. I'm holding long. Canada side will be back soon and they'll be buying.
all Business acqusition reports have been filed today.
$5 ps this time next year. I've done all the DD on this. They're by far the largest company in this fast growing sector with the best CEO. Psilocybin being decriminalized globally.
Who knows about the CFO here? Seems it would be his job to be on top of this, especially given recent CEO change?
I was offline this week, just catching up on the news. Disappointing.
What happened
Yeah? I've got some rocks I'll sell ya - that's a buying opportunity too.
And it hasn't been halted.
Followers
|
38
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
662
|
Created
|
03/02/20
|
Type
|
Free
|
Moderators |
Patents are the lifeblood of the biotech industry. Biotechnology is one of the most research-intensive industries, with companies in the sector typically investing between 40% and 50% of their revenues in research and development, compared to 13% in pharmaceuticals and 5% in the chemical industry. In many cases, IP rights can actually be the final product.
That's why Champignon Brands' ( SHRM ; SHRMF ) already impressive cache of pharmaceutical patents gives it a leg up in the competitive rush to claim market share in the nascent Psilocybin industry.
Normally, when you do clinical trials, the ideal is to own the resulting IP. Champignon is partnering with the University of Miami and Miller School of Medicine in its research work but will own 100% of the intellectual property, drug discovery, and resultant data.
Its Psilocybin Patent Portfolio will greatly help the company in the commercialization of GMO and vegan certified rapid onset treatments capable of improving health outcomes, such as depression and post-traumatic stress disorder (PTSD), as well as substance and alcohol use disorders. Even better: It can license its patented formulations to other companies as it deems fit.
Canada NewsWire
VANCOUVER, BC, Oct. 29, 2020
VANCOUVER, BC, Oct. 29, 2020 /CNW/ - Champignon Brands Inc. ("Champignon" or the "Company") (CSE: SHRM) (FWB: 496) (OTCQB: SHRMF) continues to work diligently with the British Columbia Securities Commission (the "Commission") to address the ongoing continuous disclosure review and to coordinate the revocation of the existing cease trade order. The Company will provide guidance on definitive timing for revocation as soon as possible.
The Company has submitted all requested documentation to the Commission in connection with the review of financial statements of AltMed Capital Corp. ("AltMed") for the period ended June 30, 2020, and subject to review by the Commission expects to move forward with the finalization and public filing of these statements in short order.
Continuous Disclosure Review History
On June 19, 2020, the Company was notified by the Commission that it would be subject to a continuous disclosure review. Such reviews are conducted by the Commission for the purposes of ensuring compliance with the continuous disclosure obligations imposed by applicable Canadian securities laws. In the case of the Company, this review relates to the Company's disclosure obligations since it became a reporting issuer on February 6, 2020 and includes a review of the disclosure surrounding acquisitions completed by the Company since that time.
In connection with the review, on June 19, 2020, the Commission issued a cease trade order suspending trading in the securities of the Company pending the filing of Business Acquisition Reports in connection with the acquisitions of Artisan Growers Ltd., Novo Formulations Ltd. and Tassili Life Sciences Corp. As a result of the cease trade order, trading in the common shares of the Company was suspended on the Canadian Securities Exchange.
The Business Acquisition Reports were filed by the Company on July 21, 2020, during which time the Company continued to work with the Commission to address comments received in the course of the disclosure review. As a result of the filing of the Business Acquisition Reports, on August 26, 2020, the Commission revoked the cease trade order previously issued on June 19, 2020. Concurrently with the revocation, the Commission issued a replacement cease trade order (the "Replacement Order"), pending the filing of a revised material change report (the "Material Change Report") in connection with the acquisition by the Company of AltMed.
Prior to the finalization of a revised Material Change Report, the Company is required to finalize the accounting treatment for the acquisition of AltMed, which includes compiling the financial statements of AltMed for the six-month period ended June 30, 2020 to meet disclosure requirements.
On October 27, 2020, the Commission issued an additional cease trade order pending the filing of the interim financial statements of the Company for the period ended June 30, 2020 (the "October Order").
The October Order is not expected to affect the review process or timing for the resumption of trading of the common shares of the Company as the reports required to be filed to satisfy the Replacement Order will address the outstanding items in the October Order.
For further clarity, the Company anticipates that the Replacement Order and the October Order will be revoked at the same time. The Company is working diligently with the Commission to ensure that the revocation of both the Replacement Order and October Order occurs as soon as possible.
Dr. Roger McIntyre
Chief Executive Officer
E: info@champignonbrands.com
FOR INVESTOR INQUIRIES:
Champignon Brands | Storyboard Communications
Investor Relations, Toronto, Canada
Investor Line: +1 (833) 375-9995 x611
E: champignonbrands@storyboardcommunications.com
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |